tbuckley/cabot-search huggingface dataset:
Abstract 4653: Melanocyte specific deletion of <i>Map3k1</i> reveals its role in BRAFV600E-driven melanoma
Authors: Lucas D. Trucco, Piyushkumar A. Mundra, Pablo Garcia-Martinez, Kate Hogan, Nathalie Dhomen, Valeria Pavet, Richard Marais
Journal: Cancer Research (2019)

Abstract BRAF is the most common driver oncogene in cutaneous melanoma. Activating mutations in the BRAF gene are enriched in melanomas associated with intermittent sun exposure, with the most frequent mutations occurring at codon 600, leading to a constitutive activation of the RAF/MEK/ERK signaling pathway. In previous studies, we demonstrated that ultraviolet radiation (UVR) accelerates melanomagenesis in a mouse model of melanoma driven by BRAFV600E. From whole exome sequencing analysis of the tumors we found that Map3k1 was the most recurrently mutated gene across different experimental cohorts. MAP3K1 is unique in having both a kinase and E3 ligase function, allowing it to regulate protein phosphorylation and ubiquitin-mediated proteasome degradation. The vast majority of the mutations in Map3k1 occurred within the RING domain, which contains the E2 binding site for ubiquitin-conjugating enzymes. The most prevalent non-synonymous mutations where present in codon 484 and arose as a consequence of C-to-T transitions at a dipyrimidine site, characteristic of UVR-induced DNA damage. To understand better the role of MAP3K1, we generated Tyr::CreERT2+/o;Map3k1f/f mice allowing us to conditionally delete Map3k1 specifically in the melanocytes upon topical application of tamoxifen to the dorsal skin of juvenile mice. These mice did not develop tumors, but when crossed to mice carrying a Braf+/LSL-V600E allele, all mice develop melanoma, with a shorter latency and an increased multiplicity compared to Tyr::CreERT2+/o;Braf+/LSL-V600E mice. Tumors showed similar histopathological features, but melanomas carrying Map3k1 floxed or mutant variants presented higher levels of phosphorylated ERK1/2 than those with wild-type Map3k1. In addition, analysis of expression data of human cutaneous melanomas from The Cancer Genome Atlas showed an inverse correlation between the expression of MAP3K1 and ERK2 protein levels. Taken together, our results suggest that MAP3K1 loss-of-function cooperates with BRAFV600E to drive melanoma development by increasing MEK-ERK pathway activation. Citation Format: Lucas D. Trucco, Piyushkumar A. Mundra, Pablo Garcia-Martinez, Kate Hogan, Nathalie Dhomen, Valeria Pavet, Richard Marais. Melanocyte specific deletion of Map3k1 reveals its role in BRAFV600E-driven melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4653.
Revisiting complete response in light chain amyloidosis
Authors: Surbhi Sidana, Angela Dispenzieri, David L. Murray, Ronald S. Go, Francis K. Buadi, Martha Q. Lacy, Wilson I. Gonsalves, David Dingli, Rahma Warsame, Taxiarchis Kourelis, Eli Muchtar, Suzanne R. Hayman, Prashant Kapoor, Robert A. Kyle, Nelson Leung, S. Vincent Rajkumar, Morie A. Gertz, Shaji K. Kumar
Journal: Leukemia (2019)
Abstract 17141: Mavacamten Improves Left Ventricular Relaxation and Compliance in Obstructive Hypertrophic Cardiomyopathy Through Direct Myosin Modulation
Authors: Stephen Heitner, Daniel Jacoby, Steven Lester, Anjali T Owens, Andrew Wang, Amil Shah, Sheila Hegde, Liang Fang, Amy Sehnert, Marc Semigran
Journal: Circulation (2018)

Introduction: Obstructive hypertrophic cardiomyopathy (oHCM) consists of a constellation of LV hypercontractility, LV outflow tract obstruction (LVOTO), and impaired relaxation, often resulting in dyspnea and reduced exercise capacity. In healthy dogs, the novel myosin modulator mavacamten (MAVA), decreased LV hypercontractility and improved compliance. In the PIONEER-HCM clinical study, improvements in post-exercise LVOT gradient, exercise capacity, and symptoms were reported. To examine whether MAVA could also limit residual myosin-actin cross-bridges during diastole, and improve LV compliance, its effects on diastolic indices were evaluated. Methods: In PIONEER-HCM, an open-label, multi-site, prospective study, oHCM subjects received MAVA for 12 weeks at either 10-20 mg/d (n = 11, Cohort A; 10 completed) or at 2-5 mg/d (n = 10, Cohort B). Echo-Doppler indices of LV filling and relaxation were compared at baseline to week 12. The p-values are from Wilcoxon signed rank tests, evaluating the distribution of within-subject 12-wk changes from baseline around a null of zero. Results: MAVA reduced hypercontractility in a dose-dependent fashion, with relief of LVOTO in all subjects achieving plasma MAVA concentration &gt;350 ng/ml (data previously reported). There was also an increase in mitral annular velocity during early diastole (e’ lat ). There was a concomitant reduction in E/e’ lat and increase in LV end-diastolic volume (LVEDV) consistent with improved LV compliance (Table). MAVA improved dyspnea score with a trend towards reduction in NT-proBNP. Conclusions: Administration of MAVA is associated with improvement in measures of myocardial relaxation (e’ lat ) and compliance in parallel with reduction in LVOT gradient. These findings are consistent with preclinical findings reported in healthy dogs and support additional evaluation of MAVA in patients with obstructive or non-obstructive HCM.
Mixed methods comparison of functional decline during chemotherapy, immunotherapy (IO), and/or targeted therapy in older adults with non-small cell lung cancer (NSCLC).
Authors: Melisa L. Wong, Alexander K. Smith, Christine Miaskowski, Vivek Musinipally, Harvey Jay Cohen, Vivian Lam, Melissa Mazor, Carling Jade Ursem, Kah Poh Loh, Jamie Cohen, Dianne Shumay, Anna Ordin Levin, Niharika Dixit, Janice Grandi, Louise Christie Walter
Journal: Journal of Clinical Oncology (2019)

92 Background: Functional decline during NSCLC treatment is critically important to older adults. Yet, data on functional decline—particularly during chemoIO, IO, and targeted therapy—remain limited. Additionally, the best measures to capture functional decline from the patient’s perspective remain unknown. Methods: We conducted a multisite, mixed methods prospective cohort study to characterize function during systemic NSCLC treatment and compare quantitative measures with gold standard qualitative descriptions of patients’ lived experience. Prior to and at 2 months after treatment initiation, 69 adults age &gt;65 with advanced NSCLC starting chemo, IO, and/or targeted therapy underwent geriatric assessments including instrumental activities of daily living (IADL), EORTC QLQ-C30 Physical Functioning (PF), and Life-Space Assessment (LSA). LSA measures where a person goes in their environment, how frequently, and how independently. Pretreatment functional impairment and decline at 2 months were assessed. In a qualitative substudy, 16 purposively sampled patients with diverse pretreatment function completed two semi-structured interviews (pretreatment, 2 months) to explore treatment effects on daily functioning. Grounded theory was used to code for functional decline. Using the qualitative patient experience as the gold standard, sensitivity and specificity were calculated for each functional measure. Results: Mean age was 75 (range 65-94). NSCLC treatment included IO (36%), targeted therapy (28%), chemoIO (23%), and chemo (13%). Pretreatment functional impairment was common and ~25% of patients experienced functional decline on quantitative measures at 2 months (Table). Qualitatively, 50% described functional decline at 2 months. LSA had the highest sensitivity (71%) and similar specificity (88%) as IADL and PF. Conclusions: Functional decline during NSCLC treatment is common. LSA provides a sensitive and specific patient-centered measure of function. [Table: see text]
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
Authors: Yunlong Zhao, Calvin K. Lee, Chia-Hao Lin, Rodrigo B. Gassen, Xiaozheng Xu, Zhe Huang, Changchun Xiao, Cristina Bonorino, Li-Fan Lu, Jack D. Bui, Enfu Hui
Journal: Immunity (2019)
Association of Pulmonary Hypertension With Clinical Outcomes of Transcatheter Mitral Valve Repair
Authors: Rasha Al-Bawardy, Sreekanth Vemulapalli, Vinod H. Thourani, Michael Mack, David Dai, Amanda Stebbins, Igor Palacios, Ignacio Inglessis, Rahul Sakhuja, Eyal Ben-Assa, Jonathan J. Passeri, Jacob P. Dal-Bianco, Evin Yucel, Serguei Melnitchouk, Gus J. Vlahakes, Arminder S. Jassar, Sammy Elmariah
Journal: JAMA Cardiology (2019)

Pulmonary hypertension (pHTN) is associated with increased risk of mortality after mitral valve surgery for mitral regurgitation. However, its association with clinical outcomes in patients undergoing transcatheter mitral valve repair (TMVr) with a commercially available system (MitraClip) is unknown.To assess the association of pHTN with readmissions for heart failure and 1-year all-cause mortality after TMVr.This retrospective cohort study analyzed 4071 patients who underwent TMVr with the MitraClip system from November 4, 2013, through March 31, 2017, across 232 US sites in the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy registry. Patients were stratified into the following 4 groups based on invasive mean pulmonary arterial pressure (mPAP): 1103 with no pHTN (mPAP, <25 mm Hg [group 1]); 1399 with mild pHTN (mPAP, 25-34 mm Hg [group 2]); 1011 with moderate pHTN (mPAP, 35-44 mm Hg [group 3]); and 558 with severe pHTN (mPAP, ≥45 mm Hg [group 4]). Data were analyzed from November 4, 2013, through March 31, 2017.Patients were stratified into groups before TMVr, and clinical outcomes were assessed at 1 year after intervention.Primary end point was a composite of 1-year mortality and readmissions for heart failure. Secondary end points were 30-day and 1-year mortality and readmissions for heart failure. Linkage to Centers for Medicare & Medicaid Services administrative claims was performed to assess 1-year outcomes in 2381 patients.Among the 4071 patients included in the analysis, the median age was 81 years (interquartile range, 73-86 years); 1885 (46.3%) were women and 2186 (53.7%) were men. The composite rate of 1-year mortality and readmissions for heart failure was 33.6% (95% CI, 31.6%-35.7%), which was higher in those with pHTN (27.8% [95% CI, 24.2%-31.5%] in group 1, 32.4% [95% CI, 29.0%-35.8%] in group 2, 36.0% [95% CI, 31.8%-40.2%] in group 3, and 45.2% [95% CI, 39.1%-51.0%] in group 4; P < .001). Similarly, 1-year mortality (16.3% [95% CI, 13.4%-19.5%] in group 1, 19.8% [95% CI, 17.0%-22.8%] in group 2, 22.4% [95% CI, 18.8%-26.1%] in group 3, and 27.8% [95% CI, 22.6%-33.3%] in group 4; P < .001) increased across pHTN groups. The association of pHTN with mortality persisted despite multivariable adjustment (hazard ratio per 5-mm Hg mPAP increase, 1.05; 95% CI, 1.01-1.09; P = .02).These findings suggest that pHTN is associated with increased mortality and readmission for heart failure in patients undergoing TMVr using the MitraClip system for severe mitral regurgitation. Further efforts are needed to determine whether earlier intervention before pHTN develops will improve clinical outcomes.
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Authors: Carmelo Carlo-Stella, Pier Luigi Luigi Zinzani, Brad S. Kahl, Paolo F Caimi, Melhem Solh, William Townsend, Anastasios Stathis, Elizabeth H. Cull, Mehdi Hamadani, Alexander I. Spira, Jay Feingold, David Ungar, Shui He, Yajuan Qin, John Radford
Journal: Blood (2019)
Pooled analysis of efficacy and safety in Asian patients (pts) in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials of ribociclib (RIB) plus endocrine therapy (ET)
Authors: S.-A. Im, Y.-S. Yap, J. Sohn, K.S. Lee, K.H. Jung, L.M. Tseng, S.C. Lee, K.G. Babu, Y.H. Park, I. Gounaris, M. Sondhi, A. Ridolfi, J.P. Zarate, Y.-S. Lu
Journal: Annals of Oncology (2019)
Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK
Authors: Roger Williams, Guruprasad Aithal, Graeme J Alexander, Michael Allison, Iain Armstrong, Richard Aspinall, Alastair Baker, Rachel Batterham, Katrina Brown, Robyn Burton, Matthew E Cramp, Natalie Day, Anil Dhawan, Colin Drummond, James Ferguson, Graham Foster, Ian Gilmore, Jonny Greenberg, Clive Henn, Helen Jarvis, Deirdre Kelly, Mead Mathews, Annie McCloud, Alastair MacGilchrist, Martin McKee, Kieran Moriarty, Joanne Morling, Philip Newsome, Peter Rice, Stephen Roberts, Harry Rutter, Marianne Samyn, Katherine Severi, Nick Sheron, Douglas Thorburn, Julia Verne, Jyotsna Vohra, John Williams, Andrew Yeoman
Journal: The Lancet (2019)
Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Authors: K. Yamazaki, T. Koyama, T. Shimizu, T. Takahashi, J. Watanabe, Y. Tanaka, H. Myobudani, N. Yamamoto
Journal: Annals of Oncology (2019)
Opioid usage patterns among Medicare pancreatic cancer patients according to palliative care utilization.
Authors: Zhanni Lu, Cecilia M Ganduglia Cazaban, Luis G. LeonNovelo, Sriram Yennu, Sharon H. Giordano, Hui Zhao
Journal: Journal of Clinical Oncology (2019)

14 Background: Opioid pharmacotherapy is used to manage moderate and severe pain in palliative care (PC). Pain affects 80% pancreatic cancer patients older than 65 years. We assessed the opioid utilization patterns in Medicare patients with pancreatic cancer whom did not use PC (NPC), used community-based PC (CBPC) or used hospital-based PC (HBPC). Methods: We assessed opioid use, types, dispensed days, opioid uptake rates, doses (measured by morphine equivalent doses (MEDs)), and related adverse events (AEs) after pancreatic cancer diagnosis in Medicare beneficiaries selected from the SEER-Medicare database between 2007 and 2013 using the log-binomial, generalized linear mixed, and Cox proportional hazards modeling. Results: 16,106 patients were identified (median age: 78 years; female: 55.2%), of whom 8.3% used CBPC and 19.6% used HBPC. PC users were more likely to use opioids (CBPC: 72.2% vs. HBPC: 63.4% vs. NPC: 56.3%, P&lt;.001). The most commonly prescribed opioid type in NPC, HBPC and CBPC users was fentanyl (54.1%), hydromorphone (27.7%) and morphine (26.1%). Compared to other study patients, CBPC users had shorter median dispensed days per prescription (CBPC: 3 days vs. HBPC: 4 days vs. NPC: 4 days, P&lt;.001) but higher median MEDs per prescription (CBPC: 25 mg vs. HBPC: 25 mg vs. NPC: 0.13 mg, P&lt;.001). Adjusting for demographic and clinical factors, no significantly different uptake rates of opioids were determined in PC users compared to NPC users (CBPC: RR, 1.02, P=.057; HBPC: RR, 1.002, P=.783). HBPC users had higher adjusted daily MEDs than CBPC and NPC users 3 months after diagnosis (135.1 mg/d vs. 126.5 mg/d vs. 65.7 mg/d, P&lt;.001). CBPC users had higher adjusted daily MEDs than HBPC and NPC users 3 months before death (164.3mg/d vs. 155.6 mg/d vs. 92.1 mg/d, P=.0002). CBPC users had lower but HBPC users had higher adjusted hazard ratios of delirium (CBPC: HR, 0.95, HBPC: HR, 1.26, P&lt;.001) and drowsiness (CBPC: HR, 0.94, HBPC: HR, 1.53, P&lt;.001) than NPC users. Conclusions: Older pancreatic cancer patients using PC tended to use opioids and consumed higher opioid doses. CBPC users had lower risks of opioid-related delirium and drowsiness. The factors of the opioid use variations need to be assessed.
Clare Gerada: My last Christmas on call
Authors: Clare Gerada
Journal: BMJ (2019)

For nearly 40 years I’ve been part of an on-call rota, but this Christmas will be my last on-call commitment, ever. In my first hospital jobs I was on call one in three, which included 8 am on Friday to 5 pm on Monday. As a new partner at my general practice I worked one in five, my pager never far from my side.

I still recall those night time home visits, never quite knowing where to go, with only the A-Z as a guide. In recent years I’ve gradually withdrawn from the full on-call rota, being allowed to stop the red-eye shift a few years ago, weekends more recently; …
IL-17 inhibits CXCL9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors
Authors: Ju Chen, Xiaoyang Ye, Elise Pitmon, Mengqian Lu, Jun Wan, Evan R. Jellison, Adam J. Adler, Anthony T. Vella, Kepeng Wang
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> The IL-17 family cytokines are potent drivers of colorectal cancer (CRC) development. We and others have shown that IL-17 mainly signals to tumor cells to promote CRC, but the underlying mechanism remains unclear. IL-17 also dampens Th1-armed anti-tumor immunity, in part by attracting myeloid cells to tumor. Whether IL-17 controls the activity of adaptive immune cells in a more direct manner, however, is unknown. <h3>Methods</h3> Using mouse models of sporadic or inducible colorectal cancers, we ablated IL-17RA in the whole body or specifically in colorectal tumor cells. We also performed adoptive bone marrow reconstitution to knockout CXCR3 in hematopoietic cells. Histological and immunological experimental methods were used to reveal the link among IL-17, chemokine production, and CRC development. <h3>Results</h3> Loss of IL-17 signaling in mouse CRC resulted in marked increase in the recruitment of CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) and regulatory T cells (Tregs), starting from early stage CRC lesions. This is accompanied by the increased expression of anti-inflammatory cytokines IL-10 and TGF-β. IL-17 signaling also inhibits the production of T cell attracting chemokines CXCL9 and CXCL10 by tumor cells. Conversely, the inability of hematopoietic cells to respond to CXCL9/10 resulted in decreased tumor infiltration by CTLs and Tregs, decreased levels of IL-10 and TGF-β, and increased numbers of tumor lesions. Blockade of IL-17 signaling resulted in increased expression of immune checkpoint markers. On the other hand, treatment of mouse CRC with anti-CTLA-4 antibody led to increased expression of pro-tumor IL-17. <h3>Conclusion</h3> IL-17 signals to colorectal tumor cells and inhibits their production of CXCL9/10 chemokines. By doing so, IL-17 inhibits the infiltration of CD8<sup>+</sup> CTLs and Tregs to CRC, thus promoting CRC development. Cancer immunotherapy may be benefited by the use of anti-IL-17 agents as adjuvant therapies, which serve to block both IL-17-mediated tumor promotion and T cell exclusion.
Abstract 10043: Intermittent Fasting Lifestyle and Incidence of Heart Failure and Myocardial Infarction in Cardiac Catheterization Patients
Authors: Ciera Bartholomew, Joseph B Muhlestein, Jeffrey L Anderson, Heidi T May, Kirk Knowlton, Tami L Bair, Viet T Le, Bruce Bailey, Benjamin D Horne
Journal: Circulation (2019)

Background: Intermittent fasting (IF) and longevity research has been a topic of interest for over half a century. However, studies assessing the effects of fasting on cardiac outcomes is limited. ...
Immune checkpoint inhibitor‐induced vitiligo in advanced melanoma could be related to increased levels of CCL19
Authors: T. Fujimura, K. Tanita, Y. Sato, C. Lyu, Y. Kambayashi, Y. Fujisawa, H. Uchi, Y. Yamamoto, A. Otsuka, K. Yoshino, S. Matsushita, T. Funakoshi, S. Fukushima, H. Hata, A. Hashimoto, S. Aiba
Journal: British Journal of Dermatology (2019)
Abstract 15025: A Meta-Analysis of Health-Related Quality of Life in Children, Adolescents and Adults With a Fontan Circulation
Authors: Kate H Marshall, Yves d’Udekem, Gary F Sholler, Alexander R Opotowsky, Daniel S Costa, Louise Sharpe, David S Celermajer, David S Winlaw, Nadine A Kasparian
Journal: Circulation (2019)

Introduction: People with a Fontan circulation may experience disease-related challenges alongside, or as a result, of their medical pathway. Little is known about the impact of these experiences o...
Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT
Authors: Mitja Nabergoj, Junfeng Wang, Marie Robin, Nicolaus Kröger, Emanuele Angelucci, Xavier Poire, Jakob R. Passweg, Peter Dreger, Uwe Platzbecker, Stephen Robinson, Alessandro Rambaldi, Henrik Sengeloev, Martin Bornhäuser, Matthias Stelljes, Fabio Ciceri, Jiri Mayer, Marco Ladetto, Liesbeth C. de Wreede, Linda Koster, Patrick John Hayden, Tomasz Czerw, Juan Carlos Hernandez Boluda, Donal P. McLornan, Yves Chalandon, Ibrahim Yakoub-Agha
Journal: Blood (2019)
Temporal release of a three-component protein subunit vaccine from polymer multilayers
Authors: Divakara S.S.M. Uppu, Michelle E. Turvey, Abdul Rahim Mohammed Sharif, Katell Bidet, Yanpu He, Victor Ho, Anagha D. Tambe, Julien Lescar, Ern Yu Tan, Katja Fink, Jianzhu Chen, Paula T. Hammond
Journal: Journal of Controlled Release (2019)
Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
Authors: Andrea Kuhnl, Claire Roddie, Nuria Martinez-Cibrian, Tobias F Menne, Kim Linton, Sanne Lugthart, Sridhar Chaganti, Robin Sanderson, Maria A V Marzolini, Jane Norman, Wendy Osborne, John Radford, Stephen Robinson, Ram Malladi, Piers E.M. Patten, Maeve A O'Reilly, Muhammad Saif, Geoff Shenton, Adrian Bloor, Clare J Rowntree, David A. Irvine, Orla Stewart, Arzhang Ardavan, Kate Robinson, Antonio Pagliuca, Kristian M Bowles, Graham P. Collins, Rod Johnson, Andrew K McMillan
Journal: Blood (2019)
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine
Authors: Jorge E. Cortes, Eunice S. Wang, Justin M. Watts, Sangmin Lee, Maria R. Baer, Kim-Hien Dao, Shira Dinner, Jay Yang, William B. Donnellan, Anthony P Schwarer, Christian Recher, Patrick Kelly, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, Andrew H. Wei
Journal: Blood (2019)
On Death and Dying at the Beginning of Life: Grieving the Stillborn Baby
Authors: Joyeeta G. Dastidar
Journal: The American Journal of Bioethics (2019)

Stillbirth is the leading cause of infant loss. According to the March of Dimes, 1 in 100 births in the U.S. or 24,000 births a year end in stillbirth. Medical risk factors for stillbirth include o...
Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Authors: A. Rajpurohit, V.M. Patil, V. Noronha, A. Joshi, N. Menon, A. Puranik, N. Purandare, A. Mahajan, N. Mummudi, R. Krishnatry, R. Kumar, S. Yadav, K. Prabhash
Journal: Annals of Oncology (2019)